Ganzella, M. Department of Neurobiology, MPI for Biophysical Chemistry, Max Planck Society;
http://link.springer.com/content/pdf/10.1007%2Fs11302-015-9489-9.pdf (Publisher version)
2255946_Suppl_1.tif (Supplementary material), 767KB
2255946_Suppl_2.xlsx (Supplementary material), 15KB
2255946_Suppl_3.xlsx (Supplementary material), 13KB
2255946_Suppl_4.xlsx (Supplementary material), 14KB
2255946_Suppl_5.xlsx (Supplementary material), 12KB
2255946_Suppl_6.xlsx (Supplementary material), 13KB
2255946_Suppl_7.xlsx (Supplementary material), 10KB
2255946_Suppl_8.xlsx (Supplementary material), 10KB
Ramos, D. B., Muller, G. C., Rocha, G. B. M., Dellavia, G. H., Almeida, R. F., Pettenuzzo, L. F., et al. (2016). Intranasal guanosine administration presents a wide therapeutic time window to reduce brain damage induced by permanent ischemia in rats. Purinergic Signalling, 12(1), 149-159. doi:10.1007/s11302-015-9489-9.